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Abstract
Background:  The activator protein-1 (AP-1) family of transcription factors contributes to
regulation of numerous genes involved in proliferation, apoptosis, and tumorigenesis. A wide array
of stimuli can activate AP-1, including pro-inflammatory cytokines, growth factors, tumor
promoters and stress. Numerous plant polyphenols have been shown to inhibit the activation of
AP-1, which often is ascribed to the anti-oxidant properties of these natural products.
Methods: In the present study, a library of substituted trans-stilbenes, including polyphenols, was
screened for activity against the TPA-induced activation of AP-1 using the Panomics AP-1 Reporter
293 Stable Cell Line, which is designed for screening potential inhibitors or activators.
Results: Several trans-stilbenes were identified that inhibit TPA-induced activation of AP-1, with
IC50 values as low as 0.5 μM. Moreover, some other trans-stilbenes were able to enhance the effects
of TPA 2 to 3-fold. Many of the trans-stilbenes identified as inhibitors or enhancers are devoid of
anti-oxidant properties.
Conclusion: The ability of trans-stilbenes to inhibit or enhance the effects of TPA does not depend
upon their anti-oxidant properties.
Background
Activator protein-1 (AP-1) transcription factors are homo-
or heterodimers of members of the Jun (c-Jun, JunB,
JunC), Fos (c-Fos, FosB, Fra-1, Fra-2), ATF (ATF2, ATF3, B-
ATF, JDP1, JDP2) and Maf (c-Maf, MafB, MafA, MafG/F/
K, Nrl) families of proteins, all of which are bZIP proteins.
AP-1 dimers contribute to regulation of many cellular
processes including proliferation, cell cycle regulation,
differentiation, and apoptosis [1-6]. Active AP-1 dimers
can bind to TPA-responsive elements (TREs) in the pro-
moters of AP-1 responsive genes. AP-1 binding to TREs
also is induced by growth factors, cytokines and oncopro-
teins, leading to the general view that activation of AP-1 is
oncogenic by contributing to proliferation, survival and
transformation of cells. Several AP-1 proteins, including c-
Jun and c-Fos, can transform cells in culture [7-9]. Devel-
opment of inhibitors of activation of AP-1 may be a prom-
ising approach to development of new anti-cancer
therapeutics [10,11]. However, certain AP-1 dimers can be
anti-oncogenic [4,12,13]. Whether or not AP-1 is onco-
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genic depends upon cell type, genetic background, nature
of the stimulus and state of differentiation. AP-1 is also an
important family of transcription factors involved in gene
regulation in inflammation [14].
Activation of AP-1 can be inhibited by numerous natural
product polyphenols such as resveratrol, curcumin, epi-
gallocatechin gallate and theaflavins [6,15,16]. For exam-
ple, resveratrol suppressed TNF-induced activation of AP-
1 in a variety of cells through inhibition of activation of
MAP kinases [17]. Resveratrol inhibited the TPA-induced
expression of c-Fos and c-Jun in mouse skin, also by
inhibiting MAP kinases [18,19]. In other studies, resvera-
trol inhibited anchorage-independent growth of
melanoma cells by altering the dimeric composition of
AP-1[20].
Resveratrol is a stilbene derivative. Both cis- and trans-res-
veratrol exist as natural products and both are biologically
active [21]. It is often assumed that the biological proper-
ties of resveratrol and other natural product polyphenols
are derived from their anti-oxidant properties. In the
present study, a library of substituted trans-stilbenes was
examined for activity as inhibitors or activators of the
TPA-induced activation of AP-1 in the Panomics AP-1
Reporter 293 Stable Cell Line, which is the HEK293 cell
transfected with an AP-1-dependent luciferase construct.
We report here that substituted trans-stilbenes devoid of
anti-oxidant activity can function as inhibitors of the TPA-
induced activation of AP-1. Moreover, some trans-stil-
benes can function as enhancers of the TPA-induced acti-
vation of AP-1.
Methods
Synthesis of trans-stilbenes
The synthesis of a library of substituted trans-stilbenes was
reported previously [22].
Assay of the anti-oxidant activities of trans-stilbenes
The anti-oxidant activities of the library of substituted
trans-stilbenes were determined using two standard assays
[23]. The total radical-trapping anti-oxidant parameter
(TRAP) assay measures the ability of an analog to react
with the pre-formed radical monocation of 2,2'-azinobis-
(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS.+) [24].
ABTS was reacted with potassium persulfate in the dark,
overnight, to generate the colored ABTS.+ radical cation,
which has an absorption maximum at 734 nm. The activ-
ities of the trans-stilbenes were determined by their abili-
ties to quench the color of the radical cation. The ferric
reducing/anti-oxidant power (FRAP) assay measures the
ability of an analog to reduce a ferric tripyridyltriazine
complex [25]. The ferric complex of 2,4,6-tripyridyl-s-tri-
azine was prepared at acidic pH, and the anti-oxidant
activities of the trans-stilbenes were determined by their
abilities to reduce the ferric complex to the ferrous com-
plex, monitored by formation of ferrous complex at 593
nm. In both colorimetric assays, the vitamin E analog
Trolox was used as a control.
Culturing of AP-1 reporter cells
An AP-1 reporter stable cell line derived from human
293T embryonic kidney cells transfected with a luciferase
reporter construct containing three AP-1 binding sites in
the promoter (293T/AP-1-luc, Panomics, Inc., Redwood
City, CA, USA) was grown in a humidified atmosphere at
37°C in 5% CO2/95% air. The cells were maintained in
Dulbecco's Modified Eagle's Medium (DMEM – high glu-
cose containing 4 mM glutamine) supplemented with
10% fetal bovine serum (FBS), 1 mM sodium pyruvate,
100 units/ml penicillin, 100 μg/ml streptomycin and 100
μg/ml hygromycin (Gibco/Invitrogen, Carlsbad, CA,
USA) to maintain cell selection.
Assay of the activities of substituted trans-stilbeness as 
inhibitors of the TPA-induced activation of AP-1
One day prior to treatment, the 293T/AP-1-luc cells were
plated into 24-well cell culture plates (Costar, Cambridge,
MA, USA) in the above media without hygromycin. The
following day, the cells, which were at approximately 60%
confluency, were fed fresh media with or without TPA, 10
ng/ml, (Calbiochem, USA) and immediately treated with
resveratrol or a trans-stilbene prepared in DMSO stock
solutions. The cells were placed again in a humidified
atmosphere at 37°C in 5% CO2/95% air for 24 hours.
Plate wells were gently washed with phosphate buffered
saline, pH 7.4, and lysed with 1× passive lysis buffer
(Promega, Madison, WI). The subsequent lysates were
analyzed with the Luciferase Assay System (Promega,
USA) utilizing a TD-20/20 luminometer (Turner Designs,
Sunnyvale, CA, USA). The firefly luciferase relative light
units were normalized to protein (mg/ml) with BCA™
Protein Assay Kit (Pierce, Rockford, IL, USA) and stand-
ardized to percent of control (TPA control).
Culturing of murine macrophage cells
Murine macrophage cells (BV-2) were kindly provided by
Dr. Paul M. Stemmer (Institute of Environmental Health
Sciences, Wayne State University, Detroit, MI, USA). Cells
were cultured in RPMI-1640 (Cellgro, Herndon, VA, USA)
supplemented with 10% FBS, 1 mM sodium pyruvate, 2
mM L-glutamine, 100 μg/ml streptomycin sulfate and 100
units/ml penicillin. Cells were grown on culture plates,
pre-treated with 1% gelatin for 30 min at 37°C, and pas-
saged twice weekly.
Measurement of secreted prostaglandin E2 (PGE2) levels
BV-2 cells were incubated without or with 10 ng/ml TPA.
Those cells that were treated with TPA were incubated in
parallel with resveratrol or analogs 1, 29, 46or 48at theBMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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indicated concentrations or with vehicle alone (dimethyl-
sulfoxide, 0.1% final concentration). After 24 h incuba-
tion, culture media was removed and secreted PGE2 levels
were quantified by competitive ELISA according to direc-
tions provided by the manufacturer (R&D Systems, Inc.,
Minneapolis, MN, USA).
Statistics
Error bars in figures 1, 2, 3, 4, 5, 6 represent standard devi-
ations from triplicate measurements. The ± values in
Tables 1 and 2 indicate standard deviations from triplicate
measures of IC50 from dose-response curves.
Results
Inhibition or enhancement of the TPA-induced activation 
of AP-1 by resveratrol and phenolic trans-stilbenes
Resveratrol and 7 trans-stilbenes that contained one or
more phenolic substituents were compared for their
effects on the TPA-induced activation of AP-1 in an initial
screening at 15 μM concentration of the compounds (Fig-
ure 1). Some of the compounds were strong inhibitors of
the activation of AP-1. Analog 1, which contains hydroxy
and methoxy functional groups ortho to each other on
one of the two aromatic rings, was the strongest inhibitor.
From dose-response measurements, the IC50 for 1was 0.8
μM (Table 1). By comparison, 7, which is isomeric with 1,
enhanced the TPA-induced activation of AP-1 2.5-fold.
Clearly, small changes in structure can dictate whether a
trans-stilbene inhibits or enhances the effects of TPA. Sur-
prisingly, in this screening assay, resveratrol enhanced the
effects of TPA almost 3-fold. Other compounds in this
series, such as 5and 6, had no effect. All of the trans-stil-
benes in Figure 1 retain anti-oxidant activity both in the
TRAP and FRAP assays.
Inhibition or enhancement of the TPA-induced activation 
of AP-1 by methoxy-substituted trans-stilbenes
A series of 21 methoxy-substituted trans-stilbenes contain-
ing one to four methoxy functional groups was screened
at 15 μM, as above (Figure 2). A wide range of effects was
observed. Some of these trans-stilbenes, such as 8,  9,
10and 11, were strong inhibitors of the TPA-induced acti-
vation of AP-1 with IC50 values in the range 0.7 to 3.8 μM
(Table 1). Others, such as 26, 27and 28, gave 2 to 3-fold
enhancements, comparable to resveratrol. Analogs 18, 19,
20and  21were inactive. Methoxy-substituted trans-stil-
benes, including 8, 9and 10, which were among the most
potent inhibitors, were generally devoid of anti-oxidant
activity in the TRAP and FRAP assays, indicating that anti-
oxidant activity is not essential.
Inhibition or enhancement of the TPA-induced activation 
of AP-1 by substituted trans-stilbenes devoid of hydroxy or 
methoxy functional groups
A series of 17 substituted trans-stilbenes that did not con-
tain hydroxy or methoxy functional groups was screened
at 15 μM as above (Figure 3). Several of these, such as
44and  45, which contained methyl of trifluoromethyl
groups on one of the aromatic rings, were effective
enhancers of the TPA-induced activation of AP-1, compa-
rable to resveratrol. Several others, such as 29, 30and 31,
which contained a single dimethylamino, ethoxy or
methyl functional group, were strong inhibitors (Table 1).
Many of the compounds in this series were weak inhibi-
tors or weak activators.
Inhibition or enhancement of the TPA-induced activation 
of AP-1 by para-methoxy-substituted trans-stilbenes
A series of 16 substituted trans-stilbenes that contained a
para-methoxy substituent on one ring and a variety of sub-
stituents on the second ring was screened at 15 μM (Figure
4). In this series, many compounds were strong inhibitors
of the TPA-induced activation of AP-1, such as 46, 47, 48,
49and  51(Table 1). Others were weak inhibitors or
showed no activity. None of the trans-stilbenes in this
group enhanced the TPA-induced activation of AP-1. Thus
minor changes in the nature or location of a single substit-
uent markedly affects activity. Analog 46, with an IC50 =
0.5 μM, was the most potent inhibitor observed in this
study (Table 1).
Inhibition or enhancement of the TPA-induced activation 
of AP-1 by analogs of trans-stilbenes
A series of 11 analogs of trans-stilbenes was evaluated.
This group retained a trans double bond as in trans-stil-
bene. One of the aromatic benzene rings was replaced by
a different ring. As with the other series, a range of activi-
ties was observed (Figure 5). Some compounds, such as
62and 63, were strong inhibitors (Table 1) while others,
such as 71and 72, gave enhancements comparable to res-
veratrol. Clearly, structures of inhibitors or enhancers of
the TPA-induced activation of AP-1 can differ considera-
ble from a strict trans-stilbene scaffold.
Effect of substituted trans-stilbenes on secreted 
prostaglandin E2 (PGE2) levels
To determine whether the AP-1 inhibitory effects of sub-
stituted trans-stilbenes extend beyond the 293/AP-1-luc
reporter cell line used for screening, several compounds
were selected from Table 1 and examined for capacity to
reduce levels of secreted PGE2 by a TPA-activated murine
macrophage cell line (BV-2). PGE2 is a potent inflamma-
tory mediator and product of cyclooxygenase-2 (COX-2)
activity. Since COX-2 activity is an important target for tra-
ditional anti-inflammatory reagents, such as non-steroi-
dal anti-inflammatory drugs, quantifying secreted PGE2BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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Inhibition or enhancement of the TPA-induced activation of AP-1 by resveratrol and phenolic trans-stilbenes Figure 1
Inhibition or enhancement of the TPA-induced activation of AP-1 by resveratrol and phenolic trans-stilbenes. 
Screening with the 293T/AP-1-luc cell for the effects of resveratrol and phenolic trans-stilbenes on TPA-induced activation of 
AP-1 demonstrated that resveratrol and 7were enhancers, 1, 2, 3and 4were inhibitors, and 5and 6were inactive. These phe-
nolic compounds retain anti-oxidant activity. Each value represents the average of triplicate points. Error bars show standard 
deviations. The * notation indicates p < 0.01.BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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Inhibition or enhancement of the TPA-induced activation of AP-1 by methoxy-substituted trans-stilbenes Figure 2
Inhibition or enhancement of the TPA-induced activation of AP-1 by methoxy-substituted trans-stilbenes. 
Screening with the 293/AP-1-luc cell of methoxy-substituted trans-stilbenes, which do not retain anti-oxidant activity, demon-
strated that some derivatives inhibit, some enhance and others have no effects on the TPA-induced activation of AP-1. The * 
notation indicates p < 0.01.BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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Inhibition or enhancement of the TPA-induced activation of AP-1 by substituted trans-stilbenes devoid of hydroxy or methoxy  functional groups Figure 3
Inhibition or enhancement of the TPA-induced activation of AP-1 by substituted trans-stilbenes devoid of 
hydroxy or methoxy functional groups. Screening with the 293/AP-1-luc cell of a range of substituted trans-stilbenes, 
which do not have hydroxyl or methoxy functional groups, demonstrated that some derivatives inhibit, some enhance and oth-
ers have no effects on the TPA-induced activation of AP-1. The * notation indicates p < 0.01.BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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Inhibition of the TPA-induced activation of AP-1 by para-methoxy-substituted trans-stilbenes Figure 4
Inhibition of the TPA-induced activation of AP-1 by para-methoxy-substituted trans-stilbenes. Screening with the 
293/AP-1-luc cell of a range of substituted trans-stilbenes, all of which have a para-methoxy functional group on one ring, dem-
onstrated numerous inhibitors but no enhancers of the TPA-induced activation of AP-1. Analog 46, with an IC50 = 0.5 μM, was 
the most potent inhibitor observed in this study. The * notation indicates p < 0.01.BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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Inhibition or enhancement of the TPA-induced activation of AP-1 by analogs of trans-stilbenes Figure 5
Inhibition or enhancement of the TPA-induced activation of AP-1 by analogs of trans-stilbenes. Screening with 
the 293/AP-1-luc cell of a range of analogs of stilbenes that retain the trans double bond demonstrated that inhibitors or 
enhancers of the TPA-induced activation of AP-1 can deviate considerably from the trans-stilbene scaffold. The * notation indi-
cates p < 0.01.BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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can provide a direct measurement of COX-2 expression
levels. When BV-2 cells were stimulated with TPA, levels of
secreted PGE2 were elevated by ~2-fold (Figure 6). All
compounds tested, except resveratrol, demonstrated a
dose-dependent inhibitory effect on levels of PGE2. Ana-
log 29was the most potent inhibitor as 0.1 μM was suffi-
cient to reduce PGE2 levels to those measured for
unstimulated cells. Analogs 1and  46were also able to
reduce PGE2 levels to baseline, but required doses of 10
μM, making 29~100-fold more potent that these other
trans-stilbenes. It was assumed that the measurement of
secreted PGE2 in response to treatment with resveratrol or
analogs reflects the effects of these compounds on COX-2
gene expression. It is possible that the compounds are
inhibitors of COX-2 enzyme. However, we demonstrated
previously in similar studies that focused on NF-κB-
dependent expression of COX-2 in response to LPS stim-
ulation that the inhibitory effects of resveratrol and ana-
logs were at the level of gene expression as determined by
mRNA measurements [22].
Anti-oxidant activities of enhancers and inhibitors of TPA-
induced activation of AP-1
As mentioned above and shown in Table 1, trans-stilbenes
that inhibit the TPA-induced activation of AP-1 need not
retain anti-oxidant activity, as determined by the TRAP
and FRAP assays. This same property was observed with
enhancers of the TPA-induced activation of AP-1. As
shown in Table 2, most of the compounds that enhance
activity are devoid of antioxidant activity.
Discussion
The ability of resveratrol to inhibit the stress-induced acti-
vation of AP-1 has been reported in a number of studies.
Secreted PGE2 levels after treatment of TPA-activated murine macrophage cells with substituted trans-stilbenes Figure 6
Secreted PGE2 levels after treatment of TPA-activated murine macrophage cells with substituted trans-stil-
benes. BV-2 cells were activated with TPA and co-incubated with resveratrol, 1, 29, 46, or 48. Secreted PGE2 levels were 
quantified by competitive ELISA. Basal levels of secreted PGE2 were established using non-stimulated BV-2 cells (125 pg/ml). 
Maximal PGE2 levels were determined by treating BV-2 cells with TPA alone and no inhibitor (230 pg/ml). Analog 29was the 
most potent inhibitor of PGE2 secretion. The * notation indicates p < 0.05.BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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Table 1: IC50 values of substituted trans-stilbenes as inhibitors of the TPA-induced activation of AP-1
Number Structure IC50 (μM) TRAP FRAP
1 0.8 ± 0.05 ++
8 0.7 ± 0.04 --
9 2.4 ± 0.7 --
10 3.8 ± 1.1 --
11 1.3 ± 0.03 -+
29 1.1 ± 0.1 ++
30 0.8 ± 0.1 -+
OCH3
OH
H3CO
3 OCH
H3CO
OCH3
H3CO
H3CO
OCH3
OCH3
OCH3
N(CH3)2
OCH2CH3BMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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31 1.6 ± 0.6 -+
46 0.5 ± 0.1 --
47 0.8 ± 0.1 --
48 0.8 ± 0.03 --
49 1.0 ± 0.12 --
50 0.8 ± 0.15 --
62 2.5 ± 0.5 --
Table 1: IC50 values of substituted trans-stilbenes as inhibitors of the TPA-induced activation of AP-1 (Continued)
CH3
H3CO
F
H3CO
F
H3CO
CH3
H3CO
H3 C
H3CO
Cl
H3CO
SBMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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63 2.1 ± 0.4 --
Anti-oxidant 
Activity
Table 1: IC50 values of substituted trans-stilbenes as inhibitors of the TPA-induced activation of AP-1 (Continued)
H3CO
N
In addition to suppressing TNF-induced activation of AP-
1 in a variety of cells, inhibiting TPA-induced expression
of c-Fos and c-Jun in mouse skin, and inhibiting anchor-
age-independent growth of melanoma cells [18-20], res-
veratrol suppressed TPA-induced expression of MMP-9 by
inhibition of AP-1 activation through c-Jun N-terminal
kinase (JNK) and PKC-delta pathways [26] and protected
against 4-hydroxynonenal-induced apoptosis by blocking
AP-1 signaling through JNK [27]. These and other studies
of the effects of resveratrol generally support the idea that
resveratrol prevents AP-1 activation by inhibiting
upstream kinases. However, in other studies, resveratrol
and closely related polyphenols, such as isorhaponti-
genin, inhibited AP-1 activation through suppression of
ROS-induced activation of MAP kinases by preventing the
accumulation of ROS [28]. In some studies, resveratrol
induced rather than inhibited protein expression; resvera-
trol induced COX-2 expression and nuclear accumulation
in breast cancer cells through activation of MAP kinases
and AP-1 [29]. In HT-29 cancer cells transfected with an
AP-1 reporter, resveratrol enhanced AP-1 activity induced
by TPA, similar to the present study [30]. It is apparent,
therefore, that the effects of resveratrol and related com-
pounds with respect to AP-1 signaling are cell specific,
although generally resulting in inhibition of the activa-
tion of AP-1.
These multiple studies of the biological activities of resver-
atrol generally do not address the question whether anti-
oxidant activity of resveratrol is required for the reported
biological activity. AP-1 is one of a number of redox-sen-
sitive transcription factors. AP-1 activity is regulated either
directly or indirectly through reversible oxidation-reduc-
tion of critical cysteine residues [31,32]. c-Jun and c-fos
have single conserved cysteine residues in their DNA-
binding domains that undergo reversible redox reactions
that alter their DNA-binding properties [33]. There also
are a number of AP-1-associated proteins, such as thiore-
doxin, jun activation domain-binding protein 1 (Jab1),
and redox factor-1 (Ref-1), that contribute to regulation of
the redox state of AP-1 [34,35]. The present study
addressed this question through evaluation of the effects
of trans-stilbenes, many of which did not retain anti-oxi-
dant activity, on AP-1 expression in response to TPA.
Numerous trans-stilbenes devoid of anti-oxidant activity
in the TRAP and FRAP assays were able to suppress the
TPA-induced activation of AP-1, including many of the
more potent compounds (Table 1). Clearly, anti-oxidant
activity is not essential for the ability of these trans-stil-
benes to affect activation of AP-1.
The question of the role of anti-oxidant activity in those
substituted trans-stilbenes that enhance the TPA-induced
activation of AP-1 was also addressed (Table 2). As is the
case with trans-stilbenes that inhibit the TPA-induced acti-
vation of AP-1, there is no required role for anti-oxidant
activity. In fact, most of the compounds that either sup-
pressed or enhanced TPA-induced AP-1 activity in this
study are devoid of anti-oxidant activity.
This study did not address the question of the actual tar-
gets of resveratrol and other trans-stilbenes that result in
either inhibition or enhancement of AP-1 activity in
response to TPA-induced activation of the 293T/AP-1-luc
cells. As mentioned above, the reports in the literature on
AP-1 activation suggest that numerous upstream targets,
especially protein kinases, might be involved in signaling
pathways that control the expression of AP-1. Interest-
ingly, a number of the most active analogs identified in
the current study (Table 1) were also identified in our ear-
lier study of the inhibition of expression of pro-inflamma-
tory transcription factor NF-κB in response to exposure to
LPS [22], suggesting that there may be common targets for
both the AP-1 and NF-κB pathways that are inhibited by
some of these trans-stilbenes. These targets remain to be
identified.
The possibility should be considered that the substituted
trans-stilbenes used in this study, especially those that
inhibit both AP-1 and NF-κB pathways, may target multi-
ple sites in the AP-1 and NF-κB pathways and that interac-
tions between the AP-1 and NF-κB pathways may provideBMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
Page 13 of 16
(page number not for citation purposes)
Table 2: Anti-oxidant activities of trans-stilbene that enhance the TPA-induced activation of AP-1
Number Structure % Enhancement TRAP FRAP
Resveratrol 262 ± 12 ++
7 230 ± 11 ++
25 158 ± 0.1 --
26 182 ± 21 --
27 248 ± 0.5 --
28 172 ± 12 --
41 160 ± 16 --
42 203 ± 14 --
43 220 ± 6 --
OH
OH
HO
OH
OCH3
H3CO
OCH3
H3CO
H3CO
OCH3
H3CO
OCH3
H3C
F3C
Cl
ClBMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
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44 251 ± 2 -+
45 267 ± 15 --
68 143 ± 3 --
69 164 ± 13 --
70 167 ± 4 -+
71 213 ± 29 --
72 243 ± 12 --
Anti-oxidant Activity
Table 2: Anti-oxidant activities of trans-stilbene that enhance the TPA-induced activation of AP-1 (Continued)
H3C CH3
CH3
CF3
N
S
N
N
additional complexity that contributes to cell specific
effects of these compounds. Recent studies support the
complexity of the interactions between AP-1 and NF-κB. It
was reported recently that the natural product curcumin,
which like resveratrol is a polyphenolic compounds with
multiple biological activities, is able to reduce expression
of matrix metalloproteinases (MMPs) in breast cancer
cells [36]. This was shown to involve both NF-κB and AP-
1 pathways; silencing of the p65 subunit of NF-κB was suf-
ficient to downregulate expression of AP-1 (c-jun) and
MMPs, which suggests signaling was from the NF-κB path-
way to the AP-1 pathway. It is often assumed that the
site(s) of regulation of signaling through these pathways
involves one or more of the numerous upstream kinases,
such as MAP kinases, that control the activity of AP-1 and
NF-κB. However, another recent study demonstrated that
AP-1 and NF-κB can form nuclear complexes with each
other [37].
The results shown in figure 6 for the effects of resveratrol
and several of the trans-stilbenes on expression of COX-2,
as determined by measurement of secreted PGE2, raise a
number of issues. Resveratrol did not significantly inhibit
the TPA-induced activation of COX-2 (figure 6) in a mac-
rophage cell line. In a number of studies, COX-2 induc-
tion by TPA in various cell types has been shown to
involve signaling through AP-1 [38,39] and sometimes to
involve both the AP-1 and NF-κB pathways [40]. In addi-
tion, resveratrol is reported to inhibit TPA-induced COX-
2 expression in mouse skin [19]. However, resveratrol hasBMC Pharmacology 2008, 8:19 http://www.biomedcentral.com/1471-2210/8/19
Page 15 of 16
(page number not for citation purposes)
been reported to induce COX-2 expression and nuclear
accumulation in breast cancer cells through an AP-1-
dependent pathway [29]. Thus, the effects of resveratrol
are context-dependent. This raises the question of the use-
fulness of reporter assays for screening compounds that
may inhibit signaling pathways. It may be preferable to
screen in a disease-specific manner by selecting cells that
are appropriate models for a given disease and conducting
phenotypic screens in which the appropriate disease-
related genes are monitored, such as using macrophage
cells to screen libraries for abilities to inhibit stress-
induced induction of pro-inflammatory genes and using
breast epithelial cells to screen for abilities to inhibit
stress-induced induction of pro-growth, pro-metastatic
genes.
The data in figure 6 also demonstrate that, for the few
compounds selected from Table 1, quantitatively different
results are obtained from a reporter assay compared with
a cell-specific assay. For example, analog 29is much more
effective than 46and 48in preventing TPA-induced COX-2
expression (figure 6) whereas 29is less active than 46and
48in a reporter assay (Table 1). Studies are underway to
address this issue of screening in a cell-specific manner
and evaluating the usefulness of reporter assays.
Conclusion
Substituted trans-stilbenes represent a class of compounds
that can inhibit or enhance the TPA-induced activation of
AP-1. Small changes in structure can convert an inhibitor
into an enhancer. The ability of trans-stilbenes to inhibit
or enhance the effects of TPA does not depend upon their
anti-oxidant properties.
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